Noxopharm (NOX) News Today → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free NOX Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?msn.com - February 28 at 10:40 PMGenetic Technologies Ltd. ADRwsj.com - February 17 at 5:50 PMThe morning catch up: ASX set to rise; Wall Street mixed as investors await inflation dataau.investing.com - February 12 at 6:45 PMNoxopharm extends strategic partnership with Hudson Institute of Medical Researchau.investing.com - February 12 at 6:45 PMNoxopharm Limitedafr.com - February 6 at 7:24 AMFIVE at FIVE AU: ASX logs strong day; retail figures better than expectedproactiveinvestors.com - January 10 at 5:47 PMASX December Winners: The best 50 stocks as optimism pushes markets near record highmsn.com - January 1 at 7:31 AMNoxopharm boosts cash position with A$6 million R&D rebateproactiveinvestors.com - November 15 at 5:51 PMNoxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study showsproactiveinvestors.com - October 17 at 9:15 PMASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 studymsn.com - October 17 at 9:15 PMNoxopharm soars as study shows SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammationproactiveinvestors.com - October 17 at 9:15 PMNoxopharm and Hudson Institute collaborate on pioneering mRNA researchau.investing.com - October 12 at 10:16 AMNoxopharm talks partnership with Hudson Institute of Medical Researchproactiveinvestors.com - October 11 at 10:57 PMClosing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastiemsn.com - October 4 at 8:33 AMMarket Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leadsmsn.com - October 4 at 12:30 AMASX healthcare stock Noxopharm explodes 165% on FDA newsfool.com.au - October 4 at 12:30 AMNoxopharm granted US orphan drug status for CRO-67 pancreatic cancer therapyproactiveinvestors.com.au - October 3 at 7:29 PMASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trialmsn.com - September 28 at 12:31 AMNoxopharm presents encouraging data on CRO-67 at AACR Pancreatic Cancer conferenceau.investing.com - September 28 at 12:31 AMNoxopharm welcomes preliminary data on Veyonda drug trialproactiveinvestors.com.au - May 25 at 9:38 PMNoxopharm welcomes presentation of Sofra™ inflammation technologyproactiveinvestors.com.au - May 22 at 12:14 AMNoxopharm hails new Sofra™ drug inflammation resultsproactiveinvestors.com - May 22 at 12:14 AMMarket Highlights: FAANG stocks at one-year high, and will US Fed skip a meeting in June?msn.com - May 18 at 9:11 PMNoxopharm reveals new Sofra™ drug reduces inflammationproactiveinvestors.com.au - May 18 at 9:11 PMNoxopharm has Sofra™ inflammation research presented at European Molecular Biology Organisation event; commercial opportunities awaitproactiveinvestors.com - May 17 at 10:31 PMSoft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsightfinance.yahoo.com - May 10 at 2:00 PMNoxopharm to prioritise Chroma™ and Sofra™ programs; Veyonda trials to disbandproactiveinvestors.com.au - April 5 at 8:43 PMASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030msn.com - March 28 at 2:17 AMNoxopharm reveals proprietary mRNA vaccine enhancer technologyproactiveinvestors.com - March 27 at 9:16 PMNoxopharm tapped to deliver oral presentation on lupus research at International LUPUS 2023 Conferenceproactiveinvestors.com.au - February 21 at 9:32 PMNoxopharm poised to begin efficacy phase of DARRT-2 metastatic cancer Veyonda trialproactiveinvestors.com.au - January 16 at 6:36 PMIs Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - January 14 at 8:36 PMNoxopharm autoimmune treatment pipeline bolstered with $1.5 million grant to medical research partnerproactiveinvestors.com.au - December 15 at 6:55 PMFIVE at FIVE AU: RBA delivers hard knock Christmasproactiveinvestors.com.au - December 6 at 1:40 AMNoxopharm awarded Innovation Connections Grant to support drug discoveryproactiveinvestors.com - December 5 at 8:32 PMNoxopharm’s IONIC trial advances; Veyonda oncolytic drug passes safety milestoneproactiveinvestors.com.au - December 1 at 7:53 PMProactive news headlines including Elementos Ltd, Magmatic Resources, Killi Resources and Piedmont Lithiumca.finance.yahoo.com - November 16 at 3:15 AMFIVE at FIVE AU: Strong wage data to push up rates; Trump runs again; market down but missile attack in Poland has little effectproactiveinvestors.com - November 16 at 3:15 AMNoxopharm enrols final patient cohort for CEP-2 sarcoma trial after clearing second safety milestoneproactiveinvestors.com - November 15 at 10:14 PMNoxopharm boosts cash position with $5.011 million R&D rebateproactiveinvestors.com.au - November 9 at 8:36 PMCSL invests $313m to bulk up flu, COVID-19 mRNA techafr.com - November 1 at 10:21 PMNOX.AX - Noxopharm Ltd | Stock Price & Latest News | Reutersreuters.com - September 17 at 3:09 AMSmall-cap biotech makes pancreatic cancer breakthroughafr.com - September 14 at 10:29 AMASX Health Stocks: Biotron expands COVID-19 study in Thailand; Noxopharm, Clarity progress pancreatic cancer researchmsn.com - September 14 at 1:15 AMNoxopharm reveals encouraging new pancreatic cancer preclinical study dataproactiveinvestors.com.au - September 14 at 1:15 AMNoxopharm delivers “promising” results from novel pancreatic cancer studyproactiveinvestors.com - September 14 at 1:15 AMNoxopharm and UNSW to present pancreatic cancer research at leading US oncology conferenceproactiveinvestors.com.au - August 16 at 5:42 AMNoxopharm CEP-2 sarcoma trial passes Safety Steering Committee milestoneproactiveinvestors.com.au - August 9 at 3:04 AMWill Noxopharm (ASX:NOX) Spend Its Cash Wisely?finance.yahoo.com - August 8 at 12:32 AMNoxopharm given safety committee green light to increase dose in cancer trial; Hungarian site joins upproactiveinvestors.com.au - August 1 at 8:14 PM Get Noxopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies. Find out how you can protect yourself now >>> NOX Media Mentions By Week NOX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NOX News Sentiment▼0.000.61▲Average Medical News Sentiment NOX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NOX Articles This Week▼00▲NOX Articles Average Week Get Noxopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:NOX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Noxopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.